News

Silenor could be the first and only prescription therapy for insomnia in Canada that is not a controlled substance, if approved. Paladin has gained commercialization rights to Silenor

The company has submitted new drug application (NDA) for Qnexa in October 2011. Qnexa is an investigational drug candidate being developed to address weight loss, type 2 Diabetes

The status will allow Eurogentec to manufacture a commercial bulk parenteral biopharmaceutical for one of its clients for the US market. Eurogentec CEO Jean-Pierre Delwart said they anticipate

LIGHT is a small molecule imaging agent that is believed to have potential for selective detection of tumors and metastases in a range of cancers. LIGHT is comprised

Trappsol Cyclo product is an orphan drug-designated treatment for Niemann Pick Type-C disease, also known as Childhood Alzheimer’s. The product is currently being administered in the US under

The Smarticles delivery technology has been licensed to ProNAi, for delivery of single-stranded oligonucleotide therapeutics and to Mirna for delivery of double-stranded microRNA mimics. Marina R&D executive vice

The Vitamin Finder is designed to provide consumers with accessibility to make smart choices on quality Health Mart items, reports drugstorenews. The internet based, personalized wellness-driven vitamin-recommendation tool

The agreement resolved pending patent litigation involving GLUMETZA (extended release metformin tablets) 1000mg and 500mg. According to the agreement, Lupin gains right to sell a generic version of

The CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple MyEloma (ASPIRE) trial enrolled 780 patients at approximately 200 sites. The